PBTL CD19CAR-28zeta
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Biological Agent ->
Autologous Lymphocytes -> PBTL CD19CAR-28zeta
PBTL CD19CAR-28zeta Definition
A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been genetically modified to express the chimeric antigen receptor (CAR) anti-CD19/CD3 zeta chain fusion protein coupled to the intracellular signal domain of CD28 antigen, with potential immunostimulating and antineoplastic activities. Upon administration, autologous PBTL CD19CAR-28 zeta may stimulate host cytotoxic T lymphocyte (CTL) and antibody responses against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the T-cell receptor (TCR)/CD3 complex and regulates the assembly of complete TCR complexes and their expression on the cell surface. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.
PBTL CD19CAR-28zeta Synonyms
Autologous PBTL CD19CAR-28zeta, Autologous Peripheral Blood T-Lymphocytes CD19CAR-28zeta
Terms in PBTL CD19CAR-28zeta category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.